Literature DB >> 22786625

Comparison of quantitative sweat chloride methods after positive newborn screen for cystic fibrosis.

Theresa A Laguna1, Nan Lin, Qi Wang, Bonnie Holme, John McNamara, Warren E Regelmann.   

Abstract

OBJECTIVES: Rapid and reliable confirmatory sweat testing following a positive newborn screen (NBS) for cystic fibrosis (CF) is preferred to allow for early diagnosis and to decrease parental anxiety. The Cystic Fibrosis Foundation (CFF) recently recommended a quantity not sufficient (QNS) rate of ≤ 10% in infants <3 months of age referred for quantitative sweat chloride analysis. Two CFF-approved methods are available by which to quantitatively measure chloride concentration in sweat. Our objective was to compare the performance of the Macroduct® sweat collection system (MSCS) with the Gibson and Cooke technique (GCT) in the acquisition of samples for the determination of sweat chloride concentration in infants with a positive Minnesota State NBS for CF.
METHODS: A retrospective database review of infants referred to the core Minnesota CF Center or its affiliate site for confirmatory sweat testing was performed to compare the QNS rates for the two techniques. Associations between birthweight, age at test, race, and QNS rates were examined.
RESULTS: Five hundred sixty-eight infants were referred for 616 sweat tests from March 2006 to January 2010. The mean age was 32.8 days at the initial sweat test. The GCT had a significantly higher QNS rate compared to the MSCS (15.4% vs. 2.1%, P < 0.0001). There was no association between age and the probability of QNS. The probability of QNS decreased as birthweight increased (P = 0.02). After adjusting for age, the odds of QNS using the GCT remained 8.34 (95% CI: 3.72-18.71) times that of the MSCS. Non-White infants had a significantly higher likelihood of QNS compared to non-Hispanic White infants (P = 0.0025).
CONCLUSIONS: Given the performance of the MSCS, the Minnesota CF Center has implemented the MSCS as its method of choice for diagnostic sweat testing in infants following a positive state NBS.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22786625      PMCID: PMC3856863          DOI: 10.1002/ppul.21608

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  14 in total

1.  Reliability of sweat-testing by the Macroduct collection method combined with conductivity analysis in comparison with the classic Gibson and Cooke technique.

Authors:  G Mastella; G Di Cesare; A Borruso; L Menin; L Zanolla
Journal:  Acta Paediatr       Date:  2000-08       Impact factor: 2.299

2.  Sweat testing infants detected by cystic fibrosis newborn screening.

Authors:  Richard B Parad; Anne Marie Comeau; Henry L Dorkin; Mark Dovey; Robert Gerstle; Thomas Martin; Brian P O'Sullivan
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

3.  Delayed diagnosis of cystic fibrosis and the family perspective.

Authors:  Martin Kharrazi; Lisa D Kharrazi
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

4.  Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines.

Authors:  Vicky A LeGrys; James R Yankaskas; Lynne M Quittell; Bruce C Marshall; Peter J Mogayzel
Journal:  J Pediatr       Date:  2007-07       Impact factor: 4.406

5.  Sweat-testing in preterm and full-term infants less than 6 weeks of age.

Authors:  Warren Eng; Vicky A LeGrys; Michael S Schechter; Matthew M Laughon; Pierre M Barker
Journal:  Pediatr Pulmonol       Date:  2005-07

6.  Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

Authors:  P M Farrell; M R Kosorok; M J Rock; A Laxova; L Zeng; H C Lai; G Hoffman; R H Laessig; M L Splaingard
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

7.  Psychosocial risk associated with newborn screening for cystic fibrosis: parents' experience while awaiting the sweat-test appointment.

Authors:  Audrey Tluczek; Rebecca L Koscik; Philip M Farrell; Michael J Rock
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

8.  Clinical evaluation of the macroduct sweat collection system and conductivity analyzer in the diagnosis of cystic fibrosis.

Authors:  K B Hammond; N L Turcios; L E Gibson
Journal:  J Pediatr       Date:  1994-02       Impact factor: 4.406

9.  Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

Authors:  Peter D Sly; Siobhain Brennan; Catherine Gangell; Nicholas de Klerk; Conor Murray; Lauren Mott; Stephen M Stick; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan
Journal:  Am J Respir Crit Care Med       Date:  2009-04-16       Impact factor: 21.405

10.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Authors:  Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell
Journal:  J Pediatr       Date:  2008-08       Impact factor: 4.406

View more
  3 in total

1.  Performance Evaluation of a New Coulometric Endpoint Method in Sweat Testing and Its Comparison With Classic Gibson&Cooke and Chloridometer Methods in Cystic Fibrosis.

Authors:  Yasemin Gokdemir; Pinar Vatansever; Bulent Karadag; Tuncay Seyrekel; Ozgur Baykan; Nilay Bas Ikızoglu; Refika Ersu; Fazilet Karakoc; Goncagul Haklar
Journal:  Front Pediatr       Date:  2018-05-22       Impact factor: 3.418

Review 2.  Processing Newborn Bloodspot Screening Results for CF.

Authors:  Jürg Barben; Jane Chudleigh
Journal:  Int J Neonatal Screen       Date:  2020-03-25

3.  Improving the Rate of Sufficient Sweat Collected in Infants Referred for Sweat Testing in Michigan.

Authors:  Ibrahim Abdulhamid; Mary Kleyn; Carrie Langbo; Myrtha Gregoire-Bottex; John Schuen; Krithika Shanmugasundaram; Samya Z Nasr
Journal:  Glob Pediatr Health       Date:  2014-10-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.